Therapy Areas: Respiratory
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
17 November 2026 -

Chinese pharmaceutical company Akeso Inc (HKEX:9926) announced on Monday that China's National Medical Products Administration (NMPA) has accepted its supplemental New Drug Application (sNDA) for ivonescimab in combination with chemotherapy for the first-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).

The application was previously granted Priority Review designation by the NMPA.

Akeso said that this acceptance marks the fourth marketing application submitted for ivonescimab in China and represents the first expansion of ivonescimab's clinical development into gastrointestinal cancers beyond its established lung cancer indications.

The sNDA is supported by results from the randomised, double-blind, multicentre, registrational Phase III HARMONi-GI1 study (AK112-309). The study evaluated ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy, a current global standard of care for first-line BTC. At a pre-specified interim analysis, the study met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement. All key secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR), were also met.

HARMONi-GI1 is the first Phase III study in biliary tract cancer to demonstrate a statistically significant overall survival benefit versus a PD-L1 inhibitor plus chemotherapy regimen, Akeso said.

Additionally, the Phase II/III study EA2251, conducted in collaboration with Summit Therapeutics, and the ECOG-ACRIN Cancer Research Group, has been initiated. This study will evaluate ivonescimab plus chemotherapy versus pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of advanced BTC. EA2251 represents the seventh international registrational clinical trial of ivonescimab.

Login
Username:

Password: